<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412021</url>
  </required_header>
  <id_info>
    <org_study_id>P12-769</org_study_id>
    <nct_id>NCT01412021</nct_id>
  </id_info>
  <brief_title>Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis</brief_title>
  <official_title>HumiraÂ® for Subcutaneous Injection Special Investigation ( All-case Survey ) in Patients With Juvenile Idiopathic Arthritis Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study of Humira will be conducted to clarify the following with regard to the treatment
      of juvenile idiopathic arthritis affecting multiple joints with this drug:

        -  Unknown adverse drug reactions (especially important adverse drug reactions)

        -  Incidence and conditions of occurrence of adverse reactions in the clinical setting

        -  Factors that may affect the safety and effectiveness of Humira
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2011</start_date>
  <completion_date type="Actual">April 2, 2018</completion_date>
  <primary_completion_date type="Actual">April 2, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-4/ESR at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-4/ESR at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-4/ESR at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-4/ESR at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-4/ESR at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-4/CRP at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-4/CRP at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-4/CRP at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-4/CRP at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-4/CRP at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum MMP3 Level at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum MMP3 Level at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum MMP3 Level at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum MMP3 Level at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum MMP3 Level at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Physician Global Assessment (VAS) at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Physician Global Assessment (VAS) at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Physician Global Assessment (VAS) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Physician Global Assessment (VAS) at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Physician Global Assessment (VAS) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Anti-Cyclic Citrullinated Peptide Antibodies at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Height at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Height at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Height at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Height at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Height at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Adverse Drug Reactions (ADRs)</measure>
    <time_frame>up to Week 24</time_frame>
    <description>Adverse drug reactions are defined and totaled as collected adverse events whose causal relation with adalimumab cannot be ruled out. An adverse event refers to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease associated with the use of a drug, whether or not considered related to the drug.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">375</enrollment>
  <condition>Arthritis, Juvenile Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Humira</arm_group_label>
    <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who receive Humira for the treatment of Juvenile idiopathic arthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with Juvenile idiopathic arthritis who are not responding well to
             conventional therapy and receive Humira will be enrolled in the survey

        Exclusion Criteria:

          -  Contraindications according to the Package Insert

          -  Patients who have serious infections

          -  Patients who have tuberculosis

          -  Patients with a history of hypersensitivity to any ingredient of Humira

          -  Patients who have demyelinating disease or with a history of demyelinating disease

          -  Patients who have congestive cardiac failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Package Insert Information</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <results_first_submitted>March 27, 2019</results_first_submitted>
  <results_first_submitted_qc>June 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2019</results_first_posted>
  <last_update_submitted>June 24, 2019</last_update_submitted>
  <last_update_submitted_qc>June 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis, Juvenile Rheumatoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT01412021/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT01412021/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Humira</title>
          <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="375"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Case Report Forms Locked</title>
              <participants_list>
                <participants group_id="P1" count="368"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Case Report Forms Not Retrieved</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Prior to Approval</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transferred to Other Hospital</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>safety analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>Humira</title>
          <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="356"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, Not Specified</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="356"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Activity Scale 28 (DAS28)-4/Erythrocyte Sedimentation Rate (ESR)</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.70" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DAS28-4/C-Reactive Protein (CRP)</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.42" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Matrix Metalloprotease-3 (MMP3) Level</title>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.68" spread="191.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician Global Assessment Visual Analog Scale (VAS)</title>
          <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-Cyclic Citullinated Peptide Antibody</title>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.41" spread="158.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143.86" spread="19.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.54" spread="14.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-4/ESR at Week 4</title>
        <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-4/ESR at Week 4</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>redundancy is not taken into consideration</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-4/ESR at Week 8</title>
        <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-4/ESR at Week 8</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>redundancy is not taken into consideration</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-4/ESR at Week 12</title>
        <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-4/ESR at Week 12</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>redundancy is not taken into consideration</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-4/ESR at Week 16</title>
        <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-4/ESR at Week 16</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>redundancy is not taken into consideration</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-4/ESR at Week 24</title>
        <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-4/ESR at Week 24</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>redundancy is not taken into consideration</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-4/CRP at Week 4</title>
        <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-4/CRP at Week 4</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-4/CRP at Week 8</title>
        <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-4/CRP at Week 8</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>redundancy is not taken into consideration</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-4/CRP at Week 12</title>
        <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-4/CRP at Week 12</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-4/CRP at Week 16</title>
        <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-4/CRP at Week 16</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>redundancy is not taken into consideration</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-4/CRP at Week 24</title>
        <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-4/CRP at Week 24</title>
          <description>The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
            <method_desc>redundancy is not taken into consideration</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum MMP3 Level at Week 4</title>
        <time_frame>Baseline, Week 4</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum MMP3 Level at Week 4</title>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.18" spread="138.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum MMP3 Level at Week 8</title>
        <time_frame>Baseline, Week 8</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum MMP3 Level at Week 8</title>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.36" spread="159.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum MMP3 Level at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum MMP3 Level at Week 12</title>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.05" spread="144.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum MMP3 Level at Week 16</title>
        <time_frame>Baseline, Week 16</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum MMP3 Level at Week 16</title>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-86.28" spread="178.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum MMP3 Level at Week 24</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum MMP3 Level at Week 24</title>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-98.67" spread="185.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Physician Global Assessment (VAS) at Week 4</title>
        <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Assessment (VAS) at Week 4</title>
          <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.5" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Physician Global Assessment (VAS) at Week 8</title>
        <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Assessment (VAS) at Week 8</title>
          <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.5" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Physician Global Assessment (VAS) at Week 12</title>
        <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Assessment (VAS) at Week 12</title>
          <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.8" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Physician Global Assessment (VAS) at Week 16</title>
        <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Assessment (VAS) at Week 16</title>
          <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.3" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Physician Global Assessment (VAS) at Week 24</title>
        <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Assessment (VAS) at Week 24</title>
          <description>A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.</description>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.0" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Anti-Cyclic Citrullinated Peptide Antibodies at Week 24</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>participants in the efficacy analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Anti-Cyclic Citrullinated Peptide Antibodies at Week 24</title>
          <population>participants in the efficacy analysis set with an assessment</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.03" spread="98.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0132</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Height at Week 4</title>
        <time_frame>Baseline, Week 4</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Height at Week 4</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Height at Week 8</title>
        <time_frame>Baseline, Week 8</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Height at Week 8</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Height at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Height at Week 12</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Height at Week 16</title>
        <time_frame>Baseline, Week 16</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Height at Week 16</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Height at Week 24</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Height at Week 24</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight at Week 4</title>
        <time_frame>Baseline, Week 4</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at Week 4</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight at Week 8</title>
        <time_frame>Baseline, Week 8</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at Week 8</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at Week 12</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight at Week 16</title>
        <time_frame>Baseline, Week 16</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at Week 16</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight at Week 24</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at Week 24</title>
          <population>participants in the safety analysis set with an assessment</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adverse Drug Reactions (ADRs)</title>
        <description>Adverse drug reactions are defined and totaled as collected adverse events whose causal relation with adalimumab cannot be ruled out. An adverse event refers to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease associated with the use of a drug, whether or not considered related to the drug.</description>
        <time_frame>up to Week 24</time_frame>
        <population>participants in the safety analysis set with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reactions (ADRs)</title>
          <description>Adverse drug reactions are defined and totaled as collected adverse events whose causal relation with adalimumab cannot be ruled out. An adverse event refers to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease associated with the use of a drug, whether or not considered related to the drug.</description>
          <population>participants in the safety analysis set with an assessment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADRs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious ADRs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to Week 24</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Humira</title>
          <description>Participants with juvenile idiopathic arthritis who received Humira (adalimumab).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Papillophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Gastric mucosal lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Water intoxication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Mixed connective tissue disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Juvenile idiopathic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="356"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

